News

June 29, 2016June 29, 2016

PH Associated Idiopathic Interstitial Pneumonias: EMA Says ‘No’ to Adempas (Riociguat)

The European Medicines Agency (EMA) has recommended against Adempas (riociguat) for patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP), according to a recent press release. EMA’s recommendation follows Bayer Pharmaceuticals‘ announcement in May for ... Read more

June 28, 2016June 28, 2016

New Key to Asthma Therapy Could Be Protein Interleukin 33

Asthma, News

Researchers at the University of Queensland are testing a new promising drug developed by Pfizer that could slow down the development of asthma or even reverse it. The preliminary findings using a ... Read more

June 28, 2016June 28, 2016

Analysis Shows IPF Treatment OFEV (Nintedanib) Effective in Test, Broader Criteria

Idiopathic Pulmonary Fibrosis, News

The latest analysis of Inpulsis clinical trials demonstrated that Ofev (nintedanib) for idiopathic pulmonary fibrosis slows the disease progression and that treatment results are similar using broader diagnostic criteria than required. The data was ... Read more

June 28, 2016June 28, 2016

P. aeruginosa Infections in CF Patients Aggravated by Workings of ‘Good’ Bacteria, Study Finds

Cystic Fibrosis, News

Bacteria that normally reside in the lungs, not causing disease, produce a compound that makes harmful bacterial infections with Pseudomonas aeruginosa difficult to fight. These infections can be particularly devastating for people ... Read more

June 27, 2016June 27, 2016

PHA Awards New Grants to Support Research, Patient Care

News, Pulmonary Hypertension

Marking the 25th anniversary of the Pulmonary Hypertension Association (PHA), good news was delivered at the organization’s 12th International Conference and Scientific Sessions in Dallas, via new grants for pulmonary hypertension (PH) research ... Read more

June 27, 2016June 27, 2016

Immune Genes Involved in Lung Disease Prevention Alarmingly Reduced Via E-Cigarettes

News

Researchers at the University of North Carolina (UNC), School of Medicine found that smoking E-cigarettes lowers the expression of dozens of genes involved in immune defense mechanisms responsible for prevention ... Read more

June 27, 2016June 27, 2016

Cost of Cystic Fibrosis Therapy Orkambi too High for Low Benefit, Say U.K.’s NICE

Cystic Fibrosis, News

The U.K.’s National Institute for Health and Care Excellence (NICE) announced that is does not recommend funding a cystic fibrosis (CF) treatment Orkambi through Vertex Pharmaceuticals at this time. In March, ... Read more

June 24, 2016June 24, 2016

Reata Announces Positive Interim Data on LARIAT Phase 2 Clinical Trial for PAH

News, Pulmonary Hypertension

Reata Pharmaceuticals released interim data from its extension Phase 2 LARIAT clinical trial evaluating bardoxolone methyl for the treatment of pulmonary arterial hypertension (PAH). Bardoxolone methyl is an investigational, oral, once-daily antioxidant inflammation modulator ... Read more

June 24, 2016June 24, 2016

Novartis Trial Assesses Ultibro Breezhaler For COPD Flare-Ups

COPD, News

Novartis recently announced encouraging data from a clinical trial evalutating the efficacy of once-daily Ultibro Breezhaler (indacaterol/glycopyrronium bromide) for reducing chronic obstructive pulmonary disease (COPD) flare-ups. The report was published in the New England ... Read more

June 24, 2016June 24, 2016

Pulmonary Arterial Hypertension Severity Could Be Assessed in Future with a Blood Test

News, Pulmonary Hypertension

Researchers at Johns Hopkins University School of Medicine, in Maryland, revealed that hematoma derived growth factor (HDGF) might be a good biomarker to predict disease severity in pulmonary arterial hypertension (PAH) patients. The findings were recently published ... Read more